The DNAJC25 Knockout NCI-H1975 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population in which the DNAJC25 gene has been disrupted. This loss-of-function model provides a heterogeneous pool of edited cells, enabling robust assessment of DNAJC25??s role without clonal selection artifacts. The polyclonal format preserves biological variability and is suitable for pooled population analyses in functional genomics and drug response studies.
The host cell line, NCI-H1975, is a widely used human lung adenocarcinoma epithelial model derived from a female patient with non-small cell lung cancer. It carries the clinically relevant EGFR L858R/T790M double mutation, conferring sensitivity to first- and third-generation EGFR tyrosine kinase inhibitors (TKIs) and a propensity for acquired resistance. This background makes the cells particularly valuable for investigating oncogenic signaling and therapeutic resistance mechanisms in the context of mutant EGFR.
DNAJC25 encodes a J-domain-containing Hsp40 co-chaperone that cooperates with Hsp70 molecular chaperones, such as HSPA1A and HSPA8, to regulate protein folding, trafficking, and degradation. By stimulating Hsp70 ATPase activity via its J-domain, DNAJC25 facilitates client protein binding and release, a process modulated by nucleotide exchange factors (NEFs). Its expression is transcriptionally regulated by heat shock factor 1 (HSF1) and is responsive to endoplasmic reticulum (ER) stress, positioning DNAJC25 at the intersection of the cytosolic chaperone cycle and the unfolded protein response (UPR).
In NCI-H1975 cells, DNAJC25 disruption may perturb proteostasis networks that govern oncoprotein stability and stress adaptation. Given the reliance of EGFR-mutant lung adenocarcinomas on chaperone systems for mutant receptor maturation and signaling, loss of DNAJC25 could impair Hsp70-mediated folding of key client proteins, potentially sensitizing cells to EGFR-TKI treatment or altering stress survival pathways. This knockout model thus offers a platform to dissect the contribution of co-chaperone function to EGFR-driven oncogenesis and drug resistance.
Researchers can employ these polyclonal knockout cells in a variety of assays, including western blotting and RT-qPCR for expression analysis, immunofluorescence and flow cytometry for phenotypic characterization, and functional assays such as cell viability, apoptosis, migration, and invasion to assess oncogenic behavior. Co-immunoprecipitation and proteomic studies can further elucidate DNAJC25 interactomes and client protein repertoires. Applications extend to lung cancer biology, proteostasis research, and the study of EGFR-TKI resistance mechanisms. For further information, please contact Ascent Research.
